載入...
Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate‐to‐severe plaque psoriasis: the COMPASS analysis
BACKGROUND: Guselkumab is an interleukin‐23 inhibitor indicated for the treatment of moderate‐to‐severe plaque psoriasis in adults. Guselkumab has demonstrated additional benefit in patients with early inadequate response to ustekinumab. Long‐term efficacy comparisons of guselkumab and ustekinumab a...
Na minha lista:
| 發表在: | Br J Dermatol |
|---|---|
| Main Authors: | , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
John Wiley and Sons Inc.
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7496582/ https://ncbi.nlm.nih.gov/pubmed/31652347 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjd.18634 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|